文献速递胸部肿瘤放疗

生物有效剂量与放疗方案对Ⅰ期非小细胞肺癌立体定向放疗总生存的影响

The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-08-31

该回顾性研究利用美国65个治疗中心2006—2014年T1-2 N0非小细胞肺癌单纯SBRT患者数据,分析BED10与放疗方案对总生存的影响。共纳入747例,中位BED10为132 Gy,≥105 Gy组中位生存28个月,<105 Gy组为22个月(P=.01);校正后BED10≥105 Gy仍与总生存改善相关(HR 0.78,95%CI 0.62-0.98,P=.03)。结论提示剂量提升至105 Gy BED10及以上可能改善生存。

要点

  • BED10≥105 Gy组中位生存28个月,<105 Gy组为22个月,log-rank P=.01。
  • 校正T分期、性别、组织学类型和ECOG评分后,BED10≥105 Gy与总生存改善相关(HR 0.78,95%CI 0.62-0.98,P=.03)。
  • 放疗方案(分次间隔时间)在单变量分析中不是总生存的显著预测因素。

核心结论

  • 剂量提升至105 Gy BED10及以上可能改善接受SBRT的非小细胞肺癌患者生存。

研究设计与样本

  • 回顾性队列研究,利用美国65个治疗中心2006—2014年T1-2 N0非小细胞肺癌单纯SBRT患者记录,共纳入747例。

主要发现

  • 中位BED10为132 Gy,59例(7.7%)采用连续日分次照射。
  • 中位随访41个月,452例(60.5%)死亡。
  • 581例接受≥105 Gy BED10者中位生存28个月,166例接受<105 Gy BED10者中位生存22个月(log-rank P=.01)。
  • 放疗方案在单变量分析中不是总生存的显著预测因素。
  • 校正T分期、性别、组织学类型和ECOG评分后,BED10≥105 Gy vs <105 Gy与总生存改善显著相关(HR 0.78,95%CI 0.62-0.98,P=.03)。

临床怎么用

  • 在SBRT治疗早期非小细胞肺癌时,可考虑将处方剂量提升至BED10≥105 Gy以改善总生存。

局限性

  • 本研究为回顾性分析,可能存在未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the effect of biologically effective dose (BED10) and radiation treatment schedule on overall survival (OS) in patients with early-stage non-small cell lung cancer (NSCLC) undergoing stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Using data from 65 treatment centers in the United States, we retrospectively reviewed the records of T1-2 N0 NSCLC patients undergoing SBRT alone from 2006 to 2014. Biologically relevant covariates, including dose per fraction, number of fractions, and time between fractions, were used to quantify BED10 and radiation treatment schedule. The linear-quadratic equation was used to calculate BED10 and to generate a dichotomous dose variable of <105 Gy versus ≥105 Gy BED10. The primary outcome was OS. We used the Kaplan-Meier method, the log-rank test, and Cox proportional hazards regression with propensity score matching to determine whether prescription BED10 was associated with OS. RESULTS: We identified 747 patients who met inclusion criteria. The median BED10 was 132 Gy, and 59 (7.7%) had consecutive-day fractions. Median follow-up was 41 months, and 452 patients (60.5%) had died by the conclusion of the study. The 581 patients receiving ≥105 Gy BED10 had a median survival of 28 months, whereas the 166 patients receiving <105 Gy BED10 had a median survival of 22 months (log-rank, P=.01). Radiation treatment schedule was not a significant predictor of OS on univariable analysis. After adjusting for T stage, sex, tumor histology, and Eastern Cooperative Oncology Group performance status, BED10 ≥105 Gy versus <105 Gy remained significantly associated with improved OS (hazard ratio 0.78, 95% confidence interval 0.62-0.98, P=.03). Propensity score matching on imbalanced variables within high- and low-dose cohorts confirmed a survival benefit with higher prescription dose. CONCLUSIONS: We found that dose escalation to 105 Gy BED10 and beyond may improve survival in NSCLC patients treated with SBRT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Stahl JM, Ross R, Harder EM, et al. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016. PMID: 27869080. doi:10.1016/j.ijrobp.2016.08.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。